Suven Life Sciences secures 2 US patents for new chemicals
14 September 2009
Suven Life Sciences Ltd has secured two US patents for its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The patents - US 7,507,835 and US 7,388,024 issued by the US Patent Office - on the two NECs are valid until 2022 and 2024, respectively, Suven said in a release.
Compounds using these chemicals are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention-deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia, Suven said in the release.
With these new patents, Suven has total of four granted US patents on NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, Suven said.
"We are very pleased by the grant of these patents to Suven by US Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20 billion market potential globally," said Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease.